Skip to main content

Table 1 Patients’ characteristics

From: A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

  N° (%)
  976
AGE, (years)
 Median 68
 Range 24–92
 Elderly (≥ 70) 445 (45.6)
SEX
 Male 663 (67.9)
 Female 313 (32.1)
ECOG PS
 0–1 831 (85.1)
  ≥ 2 145 (14.9)
Primary Tumor
 NSCLC 635 (65.1)
 Melanoma 183 (18.7)
 Renal cell carcinoma 135 (13.8)
 Others 23 (2.4)
No. of metastatic sites
  ≤ 2 467 (47.9)
  > 2 509 (52.1)
Type of anti-PD-1/PD-L1 agent
 Pembrolizumab 235 (24.1)
 Nivolumab 706 (72.3)
 Atezolizumab 35 (3.6)
Treatment line of Immunotherapy
 First 260 (26.6)
 Non-First 716 (73.4)
Weight (Kg)  
 Median 71
 Range 35–139
BMI (kg/m2)
 Median (range) 24.9 (13.5–46.6)
 Underweight (BMI ≤ 18.5), n°(%) 40 (4.1)
 Normal weight (BMI 18.5 < BMI ≤ 24.9), n°(%) 452 (46.3)
 Overweight (25 < BMI ≤ 29.9), n°(%) 377 (38.6)
 Obese (BMI ≥ 30), n° (%) 107 (11)